Nothing Special   »   [go: up one dir, main page]

AR057965A1 - Compuestos de lactama y metodos de uso de los mismos - Google Patents

Compuestos de lactama y metodos de uso de los mismos

Info

Publication number
AR057965A1
AR057965A1 ARP060105351A ARP060105351A AR057965A1 AR 057965 A1 AR057965 A1 AR 057965A1 AR P060105351 A ARP060105351 A AR P060105351A AR P060105351 A ARP060105351 A AR P060105351A AR 057965 A1 AR057965 A1 AR 057965A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
heterocycloalkyl
alkyl
haloalkyl
heteroaryl
Prior art date
Application number
ARP060105351A
Other languages
English (en)
Inventor
Wenqing Yao
Jincong Zhuo
Ding-Quan Qian
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR057965A1 publication Critical patent/AR057965A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Reivindicacion1: Un compuesto de formula (1) o sales aceptables para uso farmacéutico de los mismos, donde: Cy es arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2, 3, 4, o 5 -W-X-Y-Z: L es nulo, (CR12R13)q, (CR12R13)q1O(CR12R13)q2, (CR12R13)q1S(CR12R13)q2, (CR12R13)q1SO2(CR12R13)q2, (CR12R13)q1SO(CR12R13)q2, (CR12R13)q1CO(CR12R13)q2, o (CR12R13)q1CONR2a(CR12R13)q2; Q es -(CR1R2)m-A; A es cicloalquilo, heterocicloalquilo o heteroarilo, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 -W'-X'-Y'-Z-; E es -(CR3aR3b)n1-, -(CR3aR3b)n2CO-, -(CR3aR3b)n2OCO-, -(CR3aR3b)n2SO-; -(CR3aR3b)n2SO2-, -(CR3aR3b)n2NR3c-, -(CR3aR3b)n2CONR3c-, -(CR3aR3b)n2NR3cCO-, o un grupo de formula (2); D1, D2, D3 y D4 se seleccionan en forma independiente entre N y CR15; R1, R2 y R2a se seleccionan en forma independiente entre H y alquilo C1-8; R3a y R3b se seleccionan en forma independiente entre H, halo, alquilo C1-4, haloalquilo C1-4, alquenilo C2-4 y alquinilo C2-4; R3c es H, alquilo C1-4, haloalquilo C1-4, alquenilo C2-4, alquinilo C2-4, o CO-(C1-4alquilo); R4, R5, R6, R7, R8, R9, R10 y R11 se seleccionan en forma independiente entre H, OC(O)Ra', OC(O)ORb', C(O)ORb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Ra', NRc'C(O)ORb', S(O)Ra', S(O)NRc'Rd', S(O)2Ra', S(O)2NRc'Rd', ORb', SRb', halo alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, y heterocicloalquilalquilo, donde dicho alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, o heterocicloalquilalquilo, está opcionalmente sustituido con 1, 2, o 3 R14; o R4 y R5 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de entre 3 y 14 miembros que está opcionalmente sustituido con R14; o R6 y R7 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de entre 3 y 14 miembros que está opcionalmente sustituido con R14; o R8 y R9 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de entre 3 y 14 miembros que está opcionalmente sustituido con R14; o R10 y R11 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de entre 3 y 14 miembros que está opcionalmente sustituido con R14; o R4 y 6 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo fusionado de entre 3 y 7 miembros o un grupo heterocicloalquilo fusionado de entre 3 y 7 miembros que está opcionalmente sustituido con R14; o R6 y R8 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo fusionado de entre 3 y 7 miembros o un grupo heterocicloalquilo fusionado de entre 3 y 7 miembros que está opcionalmente sustituido con R14; o R4 y R9 juntos forman un puente alquileno C1-3 que está opcionalmente sustituido con R14; o R4 y R10 juntos forman un puente alquileno C1-3 que está opcionalmente sustituido con R14; o R6 y R10 juntos forman un puente alquileno C1-3 que está opcionalmente sustituido con R14; o R9 y R10 juntos forman un puente alquileno C1-3 que está opcionalmente sustituido con R14; R12 y R13 se seleccionan en forma independiente entre H, halo, alquilo C1-4, haloalquilo C1-4, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', y S(O)2NRc'Rd'; R14 es halo, alquilo C1-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Rd', NRc'C(O)ORa', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', o S(O)2NRc'Rd'; R15 es H, halo, alquilo C1-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORaö, SRaö, C(O)Rbö, C(O)NRcöRdö, C(O)ORaö, OC(O)Rbö, OC(O)NRcöRdö, NRcöRdö, NRcöC(O)Rdö, NRcöC(O)ORaö, S(O)Rbö, S(O)NRcöRdö, S(O)2Rbö, o S(O)2NRcöRdö;W, W' y Wö se seleccionan en forma independiente entre nulo, alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6, O, S, NRe, CO, COO, CONRe, SO, SO2, SONRe, y NReCONRf, donde dicho alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6 está cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, OH, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, y dialquilamino C2-8; X, X' y Xö se seleccionan en forma independiente entre nulo, alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6, arilo, cicloalquilo, heteroarilo, y heterocicloalquilo, donde dicho alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre halo, alquilo C1-6, oxo, CN, NO2, OH, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, y dialquilamino C2-8; Y, Y' y Yö se seleccionan en forma independiente entre nulo, alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6, O, S, NRe, CO, COO, CONRe, SO, SO2, SONRe, y NReCONRf, donde dicho alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6 está cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, OH, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, y dialquilamino C2-8; Z, Z' y Zö se seleccionan en forma independiente entre H, halo, CN, NO2, OH, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, y heterocicloalquilo, donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, oxo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, halosulfanilo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NReS(O)2Rb, C(=NRi)NRcRd, NRcC(=NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, y S(O)2NRcRd; donde dos -W-X-Y-Z unidos al mismo átomo forman opcionalmente un grupo cicloalquilo o heterocicloalquilo de entre 3 y 20 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 -Wö-Xö-Yö-Zö; donde dos -W'-X'-Y'-Z'- unidos al mismo átomo forman opcionalmente un grupo cicloalquilo o heterocicloalquilo de entre 3 y 20 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 -Wö-Xö-Yö-Zö; donde -W-X-Y-Z es distinto de H; donde -W'-X'-Y'-Z'- es distinto de H; donde -Wö-Xö-Yö-Zö- es distinto de H; Ra, Ra' y Raö se seleccionan en forma independiente entre H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, y heterocicloalquilo, donde dicho alquilo C1-6, haloalquilo C1-6alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo, o heterocicloalquilo; Rb, Rb' y Rbö se seleccionan en forma independiente entre H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, y heterocicloalquilalquilo, donde dicho alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo arilalquilo, heteroarilalquilo, cicloalquilalquilo, o heterocicloalquilalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo C1-6, haloalquilo C1- 6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo; Rc y Rd se seleccionan en forma independiente entre H, alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo; o Rc y Rd junto con el átomo de N al cual están unidos forman un grupo heterocicloalquilo de 4, 5, 6 o 7 miembros; Rc' y Rd' se seleccionan en forma independiente entre H alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo; o Rc' y Rd' junto con el átomo de N al cual están unidos forman un grupo heterocicloalquilo de 4, 5, 6 o 7 miembros; Rcö y Rdö se seleccionan en forma independiente entre alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo
ARP060105351A 2005-12-05 2006-12-04 Compuestos de lactama y metodos de uso de los mismos AR057965A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74235305P 2005-12-05 2005-12-05
US80867806P 2006-05-26 2006-05-26

Publications (1)

Publication Number Publication Date
AR057965A1 true AR057965A1 (es) 2007-12-26

Family

ID=38006858

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105351A AR057965A1 (es) 2005-12-05 2006-12-04 Compuestos de lactama y metodos de uso de los mismos

Country Status (15)

Country Link
US (1) US8193207B2 (es)
EP (1) EP1957494A2 (es)
JP (1) JP5475288B2 (es)
KR (1) KR101415861B1 (es)
AR (1) AR057965A1 (es)
AU (1) AU2006322060A1 (es)
BR (1) BRPI0619446A2 (es)
CA (1) CA2630492C (es)
CR (1) CR9987A (es)
EA (1) EA200870019A1 (es)
EC (1) ECSP088503A (es)
IL (1) IL191554A0 (es)
NZ (1) NZ568446A (es)
TW (1) TW200804382A (es)
WO (1) WO2007067504A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
US7687665B2 (en) * 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
WO2006012227A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006012226A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
EP1758882A4 (en) * 2004-06-24 2008-01-23 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
EA200700118A1 (ru) * 2004-06-24 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве лекарственных средств
AU2005273986A1 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
NZ554906A (en) * 2004-11-10 2011-01-28 Incyte Corp Lactam compounds and their use as pharmaceuticals
WO2006055752A2 (en) * 2004-11-18 2006-05-26 Incyte Corporation INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
EP1931652A2 (en) * 2005-09-21 2008-06-18 Incyte Corporation Amido compounds and their use as pharmaceuticals
US7998959B2 (en) * 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007089683A1 (en) * 2006-01-31 2007-08-09 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070293529A1 (en) * 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
JP2009537564A (ja) * 2006-05-17 2009-10-29 インサイト・コーポレイション 11−βヒドロキシルステロイドデヒドロゲナーゼタイプIの複素環阻害剤およびそれを用いる方法
US8835426B2 (en) * 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
AU2014218443B2 (en) * 2007-06-21 2016-05-19 Incyte Holdings Corporation Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
EP2183229B1 (en) * 2007-07-26 2012-04-18 Vitae Pharmaceuticals, Inc. Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) * 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状カルバゼート及びセミカルバジドインヒビター
CA2714532A1 (en) * 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
CA2715290A1 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5451646B2 (ja) * 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤
CA2718264A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CL2009001058A1 (es) 2008-05-01 2010-09-10 Vitae Pharmaceuticals Inc Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
WO2009134400A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2723032A1 (en) * 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2324017B1 (en) 2008-07-25 2014-12-31 Boehringer Ingelheim International GmbH INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
WO2010011314A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
WO2010127237A2 (en) * 2009-04-30 2010-11-04 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
US8507493B2 (en) * 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8329904B2 (en) * 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011029896A1 (en) * 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
CA2802528A1 (en) 2010-07-13 2012-01-19 F. Hoffmann-La Roche Ag New azacyclic compounds
US8552024B2 (en) 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
BR112013010021A2 (pt) 2010-11-02 2019-09-24 Boehringer Ingelheim Int combinações farmacêuticas para o tratamento de distúrbios metabólicos.
US9834541B2 (en) 2012-10-08 2017-12-05 Cancer Research Technology Limited 2-aminopyridine compounds
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
US10501483B2 (en) 2017-10-24 2019-12-10 Allergan, Inc. Enamines and diastereo-selective reduction of enamines
EP3553061A1 (en) * 2018-04-12 2019-10-16 Centre National De La Recherche Scientifique (Cnrs) New inhibitors of bone resorption

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2312247A1 (fr) 1975-05-30 1976-12-24 Parcor Derives de la thieno-pyridine, leur procede de preparation et leurs applications
US4439606A (en) 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
EP0273659A1 (en) 1986-12-27 1988-07-06 Takeda Chemical Industries, Ltd. Azaspiro compounds, their production and use
JP2521999B2 (ja) * 1986-12-27 1996-08-07 武田薬品工業株式会社 アザスピロ化合物
US5206240A (en) 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
JPH04334357A (ja) 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
DE4234295A1 (de) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2705343B1 (fr) 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
FR2724656B1 (fr) 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2736053B1 (fr) 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
SI0921125T1 (en) 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU1244001A (en) * 1999-10-27 2001-05-08 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
JP2001261679A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
US6547958B1 (en) 2001-07-13 2003-04-15 Chevron U.S.A. Inc. Hydrocarbon conversion using zeolite SSZ-59
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US6818772B2 (en) 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US6743864B2 (en) 2002-03-12 2004-06-01 Basell Poliolefine Italia S.P.A. Polyolefin compositions having high tenacity
AU2003240742A1 (en) 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
US20060019977A1 (en) 2002-10-18 2006-01-26 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient
WO2004058727A1 (en) * 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
WO2005007656A1 (en) 2003-07-18 2005-01-27 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
JPWO2005047286A1 (ja) 2003-11-13 2007-05-31 小野薬品工業株式会社 スピロ複素環化合物
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
CA2549651A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
WO2005063745A2 (en) 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
CN1950082B (zh) * 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
EP1745019A1 (en) 2004-05-06 2007-01-24 Pfizer Inc. Novel compounds of proline and morpholine derivatives
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
EA200700118A1 (ru) 2004-06-24 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве лекарственных средств
CA2589565A1 (en) 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1758882A4 (en) 2004-06-24 2008-01-23 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
US7687665B2 (en) 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
WO2006012226A2 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
AU2005273986A1 (en) 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN101068595A (zh) 2004-10-22 2007-11-07 默克公司 Cgrp受体拮抗剂
NZ554906A (en) 2004-11-10 2011-01-28 Incyte Corp Lactam compounds and their use as pharmaceuticals
WO2006055752A2 (en) 2004-11-18 2006-05-26 Incyte Corporation INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
JP5133702B2 (ja) 2005-01-05 2013-01-30 アボット・ラボラトリーズ 11−β−ヒドロキシステロイドデヒドロゲナーゼ1型酵素の阻害薬
CA2598610C (en) 2005-03-03 2011-05-31 F. Hoffmann-La Roche Ag 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
AU2006252781A1 (en) * 2005-06-02 2006-12-07 Janssen Pharmaceutica, N.V. Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
EP1931652A2 (en) 2005-09-21 2008-06-18 Incyte Corporation Amido compounds and their use as pharmaceuticals
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007089683A1 (en) 2006-01-31 2007-08-09 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20070213311A1 (en) 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070293529A1 (en) 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
JP2009537564A (ja) 2006-05-17 2009-10-29 インサイト・コーポレイション 11−βヒドロキシルステロイドデヒドロゲナーゼタイプIの複素環阻害剤およびそれを用いる方法

Also Published As

Publication number Publication date
ECSP088503A (es) 2008-07-30
CR9987A (es) 2008-07-29
US8193207B2 (en) 2012-06-05
EA200870019A1 (ru) 2008-12-30
EP1957494A2 (en) 2008-08-20
JP2009518408A (ja) 2009-05-07
WO2007067504A3 (en) 2007-11-08
JP5475288B2 (ja) 2014-04-16
US20070129345A1 (en) 2007-06-07
BRPI0619446A2 (pt) 2011-10-04
IL191554A0 (en) 2008-12-29
KR20080074214A (ko) 2008-08-12
AU2006322060A1 (en) 2007-06-14
NZ568446A (en) 2011-12-22
KR101415861B1 (ko) 2014-07-04
CA2630492C (en) 2015-04-14
CA2630492A1 (en) 2007-06-14
WO2007067504A2 (en) 2007-06-14
TW200804382A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
AR057965A1 (es) Compuestos de lactama y metodos de uso de los mismos
AR059726A1 (es) Moduladores de 11 beta hidroxil esteroide deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos, y metodos de uso de los mismos
RS54236B1 (en) AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICAL PRODUCTS
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR059727A1 (es) Moduladores de 11- beta hidroxil esteriode deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos , y metodos de uso de los mismos
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
ES2606197T3 (es) Moduladores pirrolidina de GPR40
AR039659A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa
HRP20150941T1 (hr) Derivati aminodihidrotiazina kao inhibitori bace u lijeäśenju alzheimerove bolesti
AR057995A1 (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas heteroarilo sustituidas como inhibidoras de quinasas janus
AR079648A1 (es) Inhibidores de la replicacion del virus de la hepatitis c
AR073480A1 (es) Benzamidas, su preparacion y su uso como medicamentos
AR057131A1 (es) Derivados de purina como inmunomodulador
AR076228A1 (es) Piperidinas sustituidas como antagonistas de ccr3
AR073530A1 (es) Inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos. inserto oftalmico
AR081331A1 (es) Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
CO5560553A2 (es) Compuestos de alquilamida n-(3-amino-2-hidroxi-propil) sustituidos
NO20071067L (no) Nye cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer.
AR066445A1 (es) Inhibidores de la proteina activadora de la 5- lipoxigenasa (flap)
AR059942A1 (es) Derivados de benzamidina y usos relacionados de los mismos
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
BRPI0512615A (pt) compostos de sulfonamida
AR055051A1 (es) Compuestos de tiazol y oxazol y composiciones farmaceuticas que los contienen.
RS54510B1 (en) IMIDAZOTRIAZINS AND IMIDAZOPYRIMIDINS AS KINASE INHIBITORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure